Frost Radar:微生物基因體治療藥 (到2020年)
Frost Radar: Microbiome Therapeutics, 2020
|出版商||Frost & Sullivan||商品編碼||979097|
|出版日期||內容資訊||英文 34 Pages
|Frost Radar:微生物基因體治療藥 (到2020年) Frost Radar: Microbiome Therapeutics, 2020|
|出版日期: 2020年12月09日||內容資訊: 英文 34 Pages||
活用了人體內部的微生物基因體 (微生物叢) 的生物醫藥品的開發，這個5年變得非常活躍。尤其是作為腸內毒素症和肥胖症，發炎性腸道疾病，癌症，再加上思覺失調症和自閉症等神經病變的治療藥的期待高漲。
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
Microbiome present in the human body has a major role to play in the overall functioning of the human body. Human microbiota consists of a diverse population of bacterial, viral and eukaryotic communities and is present on skin, nasopharynx, oral cavity, respiratory tract, gastrointestinal tract and female reproductive tract. The naturally occurring microbiota is actively involved in metabolic cycle and the performance of immune system. Today, with deeper understanding of microbiome and its role in human health, we are able to utilize microbiome for developing therapeutics. Designing microbial therapeutics has been challenging , however with the help of genetic engineering tools manipulating these naturally occurring consortia of microbiome has gained momentum in the last five years. Numerous studies are being conducted to gain deeper understanding of host-microbiome interaction for developing targeted therapeutics.A significant focus of human microbiome research has been studying the bacteria in the gut, which represent the largest community both in terms of abundance and diversity. Microbiome therapeutics companies are increasingly involved in developing therapies for dysbiosis , obesity, inflammatory bowel disease, cancer, even neurological disorders as schizophrenia and autism.
This Frost Radar profiles companies actively involved in developing microbiome therapeutics.